These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9689156)

  • 1. Requiring higher doses of erythropoietin suggests pregnancy in hemodialysis patients.
    Maruyama H; Shimada H; Obayashi H; Nakamaru T; Miyakawa Y; Goto S; Ogihara T; Takakuwa K; Tanaka K; Kishimoto H; Yuasa Y; Sakai S; Okajima H; Suzuki S; Arakawa M
    Nephron; 1998 Aug; 79(4):413-9. PubMed ID: 9689156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
    Walter J; Gål J; Taraba I
    Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
    Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient characteristics determining rHuEPO dose requirements.
    Ifudu O
    Nephrol Dial Transplant; 2002; 17 Suppl 5():38-41. PubMed ID: 12091606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients.
    Hsu SP; Peng YS; Pai MF; Hung KY; Tsai TJ
    Blood Purif; 2003; 21(3):220-4. PubMed ID: 12784047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
    Campos A; Garin EH
    Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients.
    Hirakata H; Kanai H; Fukuda K; Tsuruya K; Ishida I; Kubo M; Hirano T; Hirakata E; Kuwabara Y; Fujishima M
    Clin Nephrol; 2000 May; 53(5):354-61. PubMed ID: 11305808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
    Besarab A; Golper TA
    ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
    Matsuhashi N; Yoshioka T
    Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study).
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients.
    Shimada N; Saka S; Sekizuka K; Tanaka A; Takahashi Y; Nakamura T; Ebihara I; Koide H
    Ren Fail; 2003 Jul; 25(4):569-78. PubMed ID: 12911161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
    Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study.
    Watanabe Y; Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2016 Dec; 20(6):598-607. PubMed ID: 27928910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin.
    Takeda A; Toda T; Shinohara S; Mogi Y; Matsui N
    Am J Kidney Dis; 2002 Jul; 40(1):104-9. PubMed ID: 12087567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.